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DOI 10.1016/j.ccr.2011.03.010SUMMARYWnt canonical signaling is critical for normal development aswell as homeostasis of several epithelial tissues,
and constitutive activation of this pathway is commonly observed in carcinomas. We show here that 50% of
human sarcomas (n = 45) and 65% of sarcoma cell lines (n = 23) of diverse histological subtypes exhibit up-
regulated autocrine canonical Wnt signaling. Furthermore, in Wnt autocrine cell lines, we identify alterations
including overexpression or gene amplification of Wnt ligands and/or LRP5/6 coreceptors and epigenetic
silencing of different cell surface Wnt antagonists. Mutations in adenomatous polyposis coli (APC) gene
were observed in two nonautocrine Wnt-positive sarcoma cell lines. Finally, downregulation of the activated
Wnt pathway inhibited sarcoma cell proliferation both in vitro and in vivo by amechanism involving the down-
regulation of CDC25A.INTRODUCTION
The Wnt family of secreted proteins serves evolutionarily
conserved functions in normal development and adult tissue
homeostasis (Clevers, 2006). Wnt signaling through its receptors
activates intracellular-signaling networks for at least three
distinct pathways, including canonical Wnt/b-catenin, nonca-
nonical planar cell polarity, and Wnt/Ca2++ pathways (MacDon-
ald et al., 2009; van Amerongen and Nusse, 2009). The canonical
Wnt signaling is initiated when a Wnt ligand binds to a cell
surface receptor complex consisting of Frizzled (Fz) and low-
density lipoprotein receptor-related proteins (LRPs) 5 and 6,
leading to the phosphorylation of LRP5/6 coreceptors. This
ligand-receptor interaction further results in the inactivation of
a degradation complex, consisting of adenomatous polyposis
coli (APC), axin, and glycogen synthase kinase 3 (GSK3)b, which
in the absence of Wnt ligand, targets b-catenin for proteosomal
degradation (Clevers, 2006). b-Catenin then accumulates in the
cytoplasm, translocates to the nucleus, and binds to T cell-
specific transcription factor/lymphoid-enhancer binding factorSignificance
Sarcomas comprise the most common malignancy of childho
ences the maintenance of mesenchymal stem cells, and our fi
lation of Wnt autocrine signaling, which acts to increase their p
gene, CDC25A, a major regulator of cell cycle progression. T
diverse human sarcomas identifies Wnt signaling as a poten
mortality from this disease.(TCF/LEF) complex to modulate TCF-dependent transcription
of target genes. Certain TCF/b-catenin target genes, including
AXIN2, c-MYC, and LEF1, appear to be transcriptionally upregu-
lated in a tissue-independent manner, whereas other target
genesmay be tissue or context specific (He et al., 1997; Hovanes
et al., 2001; Jho et al., 2002; Leung et al., 2002).
Wnt signaling is kept in check at multiple levels through
receptor downregulation (Khan et al., 2007) and feedback-nega-
tive regulators such as AXIN2 and DKK1 (Bafico et al., 2001;
Jho et al., 2002;Wu et al., 2000). DKKs bind to LRP5/6 and inhibit
Wnt canonical signaling (Bafico et al., 2001; Mao et al., 2001;
Semenov et al., 2001; Tamai et al., 2000). Another class of antag-
onists, FRPs, binds to and sequesters Wnts, blocking both
canonical and noncanonical signaling (Bafico et al., 1999;
Rattner et al., 1997). Wnt/b-catenin signaling is involved in the
maintenance of normal tissue stem/progenitors of epithelial
tissues, including the gastrointestinal tract, skin, mammary
gland, and lung (Radtke and Clevers, 2005; Reya and Clevers,
2005). Carcinomas that arise in these same tissues often exhibit
aberrant Wnt pathway activation by mechanisms such asod and afflict adults as well. Canonical Wnt signaling influ-
ndings indicate that sarcomas commonly select for upregu-
roliferation through the functions of a TCF/b-catenin target
he high frequency at which the Wnt pathway is activated in
tial target for therapies that could decrease morbidity and
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Figure 1. High Frequency of Upregulated
Canonical Wnt Activity in Human Sarcomas
and Sarcoma Lines of Multiple Histological
Subtypes
(A) Total cell lysates were subjected to precipita-
tion with a glutathione S-transferase (GST)-E
cadherin fusion protein (Bafico et al., 1998) fol-
lowed by immunoblot analysis with mAb directed
against b-catenin. a-Tubulin was used as a loading
control.
(B) TCF luciferase reporter activity in human
sarcoma cells. Results are depicted as the ratio of
TOP/FOP luciferase activity at 72 hr after trans-
duction. Error bars indicate SD of mean values
obtained from triplicates and are representative of
two independent experiments.
(C) Protein extracts from frozen sections of primary
sarcoma tissues were subjected to analysis of
uncomplexed b-catenin levels, total b-catenin, and
b-actin as in (A). 53S and MDAMB361 cell lysates
served as positive and negative controls (Bafico
et al., 2004). A representative blot is shown.
(D) Frequency of elevated uncomplexed b-catenin levels in primary sarcomas. Results reflect at least two independent analyses for each tumor specimen. LMS,
leiomyosarcoma; FS, fibrosarcoma; SS, synovial sarcoma; ES or EW, Ewing’s sarcoma; OS, osteosarcoma; GS, gliosarcoma; PS, pleomorphic; LS, liposarcoma;
GIST, gastrointestinal stromal tumor; RD or RMS, rhabdomyosarcoma.
See also Figure S1.
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Upregulation of Wnt Activity in Human Sarcomasmutations of APC, CTNNB1, or AXIN (Giles et al., 2003; Polakis,
2000) and more recently through autocrine Wnt activation (Akiri
et al., 2009; Bafico et al., 2004).
Wnt signaling is also among the developmental pathways that
regulate the self-renewal and differentiation of mesenchymal
stem cells (MSCs) (Hartmann, 2006; Jaiswal et al., 2000;
Siddappa et al., 2008; Tezuka et al., 2002). MSCs isolated from
bone marrow can differentiate along osteogenic, chondrogenic,
adipogenic, connective tissue, as well as myogenic lineages
(Pittenger et al., 1999). Sarcomas, which account for themajority
of pediatric malignancies (Jemal et al., 2008), and occur in adults
as well, involve mesenchymal tissues and comprise a diverse
array of histological subtypes (Skubitz and D’Adamo, 2007).
MSCs have been identified as the targets of ‘‘first-hit’’ in Ewing’s
sarcoma and malignant fibrous histiocytoma (MFH) (Matushan-
sky et al., 2007; Miyagawa et al., 2008; Tirode et al., 2007).
We recently showed that human MSCs (hMSCs) exhibit low
levels of endogenous Wnt signaling and that whereas the
addition of exogenous Wnt to these cells promoted their self-
renewal, excessWnt inhibited hMSC differentiation along osteo-
genic or adipogenic lineages (Liu et al., 2009). Based on these
findings, the major goal of the present study was to investigate
the role of canonical Wnt pathway in human sarcomagenesis.RESULTS
Detection of Increased Wnt Activity in a High Fraction
of Human Sarcomas of Diverse Histological Types
To investigate a possible role of Wnt pathway activation in
sarcomas, we screened human tumor lines representing major
sarcoma subtypes for canonical Wnt activity. We identified upre-
gulated Wnt signaling relative to that observed in hMSCs as
evidenced by increased levels of uncomplexed b-catenin
(Figure 1A; see Figure S1 available online) and increased TCF602 Cancer Cell 19, 601–612, May 17, 2011 ª2011 Elsevier Inc.reporter activity (Figure 1B) in 17 of 23 tumor lines analyzed
including those derived from Ewing’s, fibro-, leiomyo-, lipo-, os-
teo-, rhabdomyo-, and synovial sarcoma (Figure S1). We next
screened both soft tissue and bone sarcomas for uncomplexed
b-catenin levels. Figure 1C shows a representative blot for
uncomplexed b-catenin levels in different subtypes of sarcoma
cell lines relative to 53S, a previously reported Wnt-activated
tumor line (Bafico et al., 2004). Among a total of 45 primary
sarcomas analyzed, Wnt activation was observed in 25, repre-
senting 12 different histological subtypes (Figure 1D). These
results demonstrate that the Wnt canonical pathway is upregu-
lated in a large fraction of human sarcoma cell lines and
sarcomas of diverse subtypes.Wnt Activation in Human Sarcomas Involves Multiple
Mechanisms
We initially surveyed eachWnt-positive tumor line for evidence of
b-catenin activating lesions, a commonly observed mechanism
for Wnt activation in tumors (Polakis, 1999), but found none
among 11 lines tested. To test whether constitutiveWnt pathway
activation in these sarcoma lines was due to an autocrine loop,
we treated sarcoma cells with either DKK1 or FRP.Many showed
pathway inhibition in response to DKK1 and/or FRP (Figures 2A
and 2B), supporting an autocrine mode of Wnt pathway
activation in these sarcoma lines. Neither treatment inhibited
the upregulated Wnt pathway in two cell lines, A2984 and
SK-UT-1 (Figures 2B; Figure S1). Thus, we analyzed these lines
for APC alterations by western blotting and detected truncated
APC proteins in both cell lines (Figure S2D). We then searched
the Sanger Institute database on somatic mutations in cell lines
and found that SK-UT-1 had been identified as having heterozy-
gous APC mutations, consistent with our results of immunoblot
analysis. We confirmed these mutations by sequence analysis
(data not shown) and identified an insertion of ‘‘G’’ base at
Figure 2. Wnt Autocrine Activation in
Human Sarcomas Occurs Commonly and
Is Associated with Several Pathway Aberra-
tions
(A) Effects of DKK1 on Wnt/b-catenin signaling in
human sarcoma cells. Cells were treated with
DKK1 for 3 hr followed by analysis of uncomplexed
b-catenin levels as described in Figure 1A.
(B) Wnt-activated sarcoma lines resistant to DKK1
inhibition were stably infected with human FRP
followed by immunoblot analysis as described
in (A).
(C) Real-time PCR analyses for various canonical
Wnt ligands were conducted on total RNAs.
Normalized values are represented relative to
those in hMSC.
(D) Protein extracts from whole-cell lysates of
different human sarcoma lines and hMSCs were
subjected to immunoblot analysis.
(E) Real-time PCRwas performed on genomic DNAs extracted from the indicated sarcoma lines to analyze LRP5 gene copy number. SUV420H1 andGAL are two
flanking genes 50 and 30 of LRP5, respectively. Albumin was used as a standard for diploid gene copy number. Normalized values are represented relative to those
in normal human epithelial cells. Error bars indicate SD of mean values obtained from triplicates and are representative of two independent experiments.
See also Figure S2.
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Upregulation of Wnt Activity in Human Sarcomas4790_4791, resulting in an amino acid substitution of alanine to
glycine and the generation of a premature stop codon in A2984
sarcoma line (Figure S2D).
To further investigate the mechanisms involved in autocrine
Wnt activation, we analyzed expression levels of various canon-
ical Wnt ligands and antagonists. The relative mRNA levels of
Wnt ligands analyzed varied among sarcoma cell lines, but
each line exhibited much higher levels of at least some Wnts
capable of triggering canonical signaling when compared to
hMSCs (Figure 2C). Additionally, some sarcoma lines showed
much higher levels of LRP5 and/or LRP6 protein expression
compared to hMSCs (Figure 2D). HOS and G-292 cells showed
markedly increased LRP5mRNA (Figure S2A) and protein levels
(Figure 2D), and also exhibited increased LRP5 gene copy
number (Figure 2E) when compared to flanking genes. In other
sarcoma lines with increased LRP5/6 protein levels, there was
no significant increase in the transcript level of either gene,
implying that increased protein stabilization was responsible.
In a subset of the sarcoma cell lines in our series, reduced
expression of one or more Wnt antagonists correlated with the
presence of promoter methylation (Figure S2B). Figure S2C
summarizes relative expression levels of both positive and nega-
tive cell surface regulators of the Wnt pathway in sarcoma lines
with Wnt pathway activation compared to hMSCs.Identification of CDC25A as a TCF/b-Catenin Target
Gene in Wnt-Activated Human Sarcoma Cells
In a microarray experiment conducted to discover potential
targets of Wnt signaling in hMSCs, we identified CDC25A, an
important regulator of cell cycle (Boutros et al., 2007), to be up-
regulated markedly in response to WNT3A treatment (Table S1)
and validated this result by real-time PCR and western blotting
(Figures 3A; Figure S3). As shown in Figure 3A, the relative
expression levels of CDC25A and AXIN2 increased by more
than 4-fold within 6 hr of hMSC treatment with WNT3A. Expres-
sion levels of the other two CDC25 family members did not
increase under these same conditions. Sarcoma lines of diversesubtypes with Wnt activation also showed preferential expres-
sion of CDC25A compared to hMSCs (Figure 3B). Moreover,
analysis of a primary human sarcoma, which was positive for
nuclear b-catenin by immunostaining, also stained positive for
nuclear CDC25A, whereas the paired normal tissuewas negative
for both (Figure 3C). It should be noted that CDC25A protein
expression level and the level of Wnt activation did not uniformly
correlate among the sarcoma lines analyzed, which may be ac-
counted for by the complexity of CDC25A regulation at post-
translational as well as transcriptional levels (reviewed in Boutros
et al., 2007).
To determine whether CDC25A was a direct TCF/b-catenin
transcriptional target, we performed an in silico analysis of the
CDC25A promoter and identified two putative TCF-binding
(TCFB) sites within a 1.3 kb fragment upstream of the first
exon (Figure 3D). Chromatin immunoprecipitation (ChIP) per-
formed on DNA extracted from Wnt-activated U-2 OS cells
revealed that b-catenin associated with the two putative TCFB
sites in theCDC25A promoter and at a similar site present within
the AXIN2 promoter (Figure 3D). When the CDC25A reporter was
cotransfected with a constitutively activated S33Y b-catenin in
HEK293T cells, we observed a dose-dependent increase in
reporter activity (Figure 3E). Moreover, the observed CDC25A
promoter activity was inhibited when the putative TCFB sites
(DTCFB) in the CDC25A promoter were mutated (Figure 3F),
further establishing CDC25A as a direct transcriptional target
of canonical Wnt signaling.Downregulation of Activated Wnt Signaling Inhibits
Human Sarcoma Proliferation In Vitro and In Vivo
To address the biological significance of upregulated Wnt
signaling in human sarcoma cells, we transduced tumor lines
representing four distinct sarcoma subtypes exhibiting either au-
tocrineWnt activation orAPC truncationmutations,with a consti-
tutive dnTCF4 lentivirus. Using this strategy, we observed
greater than 50% inhibition of TCF reporter activity (Figure 4A)
associated with markedly decreased colony-forming ability inCancer Cell 19, 601–612, May 17, 2011 ª2011 Elsevier Inc. 603
Figure 3. CDC25A Is a Direct TCF/b-Cate-
nin Transcriptional Target
(A) hMSCs were treated with 100 ng/ml of WNT3A
for either 6 or 24 hr, and total RNA was extracted.
Real-time PCR was conducted to measure the
mRNA expression changes for the indicated
genes as described in Figure 2C.
(B) Whole-cell lysates of different human sarcoma
lines and hMSCs were subjected to immunoblot
analysis for expression of CDC25A.
(C) Uncomplexed b-catenin levels in a primary
human leiomyosarcoma and corresponding adja-
cent normal tissue were determined as described
in Figure 1. Protein extracts from tissues were
subjected to immunoblot analysis with specific
antibodies to b-catenin and CDC25A (top). Im-
munostaining for b-catenin or CDC25A was per-
formed on frozen sections (bottom) from the same
leiomyosarcoma and corresponding normal tissue
as used for western blotting above. Scale bar
indicates 50 mm.
(D) Schematic representation of CDC25A
promoter region containing putative TCFB
elements (top) and ChIP assay in autocrine Wnt-
activated U-2 OS osteosarcoma cells (bottom).
(E) Empty PGL2 luciferase reporter vector or
a reporter construct containing the 1.3 kb
promoter region of CDC25A was transfected into
HEK293T cells with or without an expression
vector for constitutively active S33Y-b-catenin.
Luciferase reporter activities were measured 48 hr
posttransfection.
(F) Site-directed mutagenesis was used to mutate
the two putative TCFB elements in the 1.3 kb
CDC25A promoter region. Wild-type or mutant
CDC25A reporter constructs (200 ng each) were cotransfected with a constitutively active S33Y-b-catenin expression construct (50 ng) in HEK293T cells.
Luciferase activities were measured 48 hr posttransfection and normalized to Renilla as in (E). ***p < 0.001 by Student’s t test. Error bars indicate SD of mean
values from triplicates and are representative of two independent experiments.
See also Figure S3 and Table S1.
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Upregulation of Wnt Activity in Human Sarcomassarcoma cells having either mechanism of Wnt activation (Fig-
ure 4B). As a specificity control, dnTCF4 expression did not
significantly alter colony formation by A1673, a sarcoma line
with very low or undetectable levels of uncomplexed b-catenin
(Figures 1A and 4B). Analyses of cell cycle profiles of sarcoma
lines expressing dnTCF4 indicated that growth inhibition was
achieved either via G1 or G2 arrest (Figure 4C). We also tested
the effects of shRNA knockdown of either LRP5 or LRP6 in
HOS and A204 sarcoma lines, which exhibited high levels of
endogenous LRP5 and LRP6 proteins, respectively. Downregu-
lation of these receptors led to a concomitant decrease in Wnt
reporter activity and inhibition of in vitro proliferation (Figure S4A),
implying the involvement of these overexpressed receptors in
autocrine Wnt-mediated proliferation of these sarcoma lines. In
addition, the ectopic expression of a constitutively active b-cat-
enin rescued FRP-mediated inhibitory effects of Wnt downregu-
lation on in vitro proliferation, further confirming the involvement
of the canonical Wnt pathway (Figure S4B).
Because CDC25A plays a crucial role in both G1/S and G2/M
progression (reviewed in Boutros et al., 2007), we further
analyzed CDC25A levels in representative Wnt-activated
sarcoma cell lines. We observed in all cases that CDC25A
protein (Figure 4D) and mRNA (Figure S4C) levels were signifi-
cantly reduced when Wnt signaling was inhibited by dnTCF4604 Cancer Cell 19, 601–612, May 17, 2011 ª2011 Elsevier Inc.aswell as by DKK1, FRP, and shRNA directed against LRP5 (Fig-
ure S4D). Each approach downregulated CDC25A transcript
levels comparably to AXIN2. In contrast, there were no signifi-
cant effects on CDC25B and CDC25C mRNA levels under the
same conditions. Furthermore, DKK1 inhibition of CDC25A
expression was detectable by 36 hr, prior to any observable
alteration of cell cycle profile (Figure S4E). For comparison, we
also measured transcript levels of the three CDC25 genes in
HT1080 sarcoma cells synchronized either at G1/S or G2/M
phases. Expression levels of all three CDC25 genes showed
similar decreases in cells arrested in G1/S (Figure S4F), whereas
Wnt pathway inhibition by dnTCF4 resulted in specific downre-
gulation of CDC25A transcript levels as indicated above. All of
these results argue that CDC25A downregulation observed as
a result of Wnt pathway inhibition is not due to a cell cycle posi-
tional effect and confirm our conclusions thatCDC25A is a direct
Wnt transcriptional target gene.
Wenext compared the effects of downregulating TCFsignaling
or CDC25A in Wnt autocrine HT1080 cells. Constitutive dnTCF4
expression significantly inhibited tumor formation (Figures 5A
and 5B), confirming the inhibition of cell proliferation observed
in vitro (Figure 4B). Of note, exogenous CDC25A expression in
these same cells rescued in vivo tumor growth (Figure 5A),
whereas downregulation of CDC25A alone using a specific
Figure 4. Downregulation of Activated Wnt Signaling in Human Sarcoma Cells Induces Inhibition of Proliferation In Vitro
(A) Downregulation of Wnt signaling in sarcoma lines constitutively expressing lentiviral-transduced dnTCF4 was assessed by TCF luciferase reporter assay as in
Figure 1B. Error bars indicate SD of mean values from triplicates and are representative of two independent experiments (top). Western blot analysis was
performed using whole-cell lysates from sarcoma lines expressing dnTCF4 (bottom).
(B) Human sarcoma lines were transduced with either vector control or dnTCF4-expressing lentiviruses. In vitro proliferation was assessed by colony-forming
assays. Results are representative of at least two independent experiments.
(C) Cell cycle profile analysis of sarcoma cells stably expressing dnTCF4 performed by FACS.
(D) Cell lysates from sarcoma lines expressing dnTCF4 were subjected to immunoblot analysis for CDC25A, c-MYC, and p21.
See also Figure S4.
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formation (Figures 5A and 5B). Ectopic CDC25A also rescued
dnTCF4-mediated inhibition of cell proliferation with several
additional Wnt-activated sarcoma cell lines analyzed (Fig-
ure S4G). These findings establish that Wnt signaling through
the TCF/b-catenin target gene, CDC25A, contributed signifi-
cantly to tumor formation of these Wnt-activated sarcomas.
Comparative Analysis ofCDC25A and c-MYCExpression
Identifies CDC25A as a Major Mediator of b-Catenin
Driven Sarcoma Cell Proliferation
c-MYC is a direct Wnt transcriptional target in colon and other
carcinoma cells (Finch et al., 2009; He et al., 1998; Sansom
et al., 2007; van de Wetering et al., 2002) As shown in Figure 6,dnTCF4 expression reduced c-MYC levels in HCT116, a b-cate-
ninmutated colon cancer line reported to have high Wnt activity
(He et al., 1998; Morin et al., 1997; Suzuki et al., 2004) (Figure 6A,
lanes 1–2). In contrast, downregulation ofWnt signaling in several
sarcoma lines failed to significantly affect c-MYC levels, although
CDC25A levels were reduced in each case (Figure 4D and Fig-
ure 6A, lanes 3–8). The CDK inhibitor, p21, is a known c-MYC
repression target and is upregulated in response toc-MYCdown-
regulation in colon (van de Wetering et al., 2002) and other
Wnt-activated carcinomas (Akiri et al., 2009; Bafico et al., 2004;
van deWetering et al., 2002). However,Wnt-signaling downregu-
lation had no effect on p21 levels in the sarcoma lines analyzed
(Figure 4D). Whereas WNT3A significantly induced CDC25A
expression in hMSCs (Figure 3A),WNT3A treatment of these cellsCancer Cell 19, 601–612, May 17, 2011 ª2011 Elsevier Inc. 605
Figure 5. Downregulation of Activated Wnt Signaling in HT1080, a Human Fibrosarcoma Cell Line, Induces Inhibition of Proliferation In Vivo
(A) HT1080 cells stably expressing firefly luciferase were transduced with lentiviruses expressing the indicated genes and marker selected. Cells (1 3 106) were
injected subcutaneously in nude mice (n = 4), and whole animal imaging was performed 6 weeks post-inoculation.
(B) Graph showing tumor growth over timemeasured by calipers. Each data point represents amean of eight values (n = 4mice/group), and error bars indicate SD
of mean values. **p < 0.01, ***p < 0.001 by two-way ANOVA.
(C) Lysates from HT1080 cells expressing the indicated constructs prior to inoculation in mice were subjected to immunoblot analysis.
(D) Real-time PCR was conducted to measure the mRNA expression changes for the specified genes as described in Figure 2C. Error bars indicate SD of mean
values from triplicates.
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(Figure 6B), another reportedWnt target gene (Tetsu andMcCor-
mick, 1999). These results indicate that neither is a direct tran-
scriptional target of Wnt signaling in hMSCs. All of these findings
argue thatCDC25A, but not c-MYC, is a TCF/b-catenin transcrip-
tional target in hMSCs and sarcoma cells.
When we analyzed c-MYC protein levels in human sarcoma
lines, strikingly, most exhibited upregulated c-MYC expression
as compared to hMSCs (Figure 6C). Primary sarcomas also
exhibited increased c-MYC protein levels compared to their
normal tissue counterparts (Figure 6D). These results imply
that a Wnt-independent mechanism involving increased protein
stabilization frequently increases c-MYC protein expression in
sarcomas. Moreover, both c-MYC and CDC25A-specific
shRNAs inhibited in vitro proliferation of A2984 and HT1080
sarcoma as well as HCT116 carcinoma cells, implying that
both genes contribute significantly to proliferation of these tumor
cells (Figure S5). CDC25A is also known to be a c-MYC tran-
scriptional target gene in mammalian cells (Galaktionov et al.,
1996). To test whether CDC25A was also a direct TCF/b-catenin
target in carcinoma cells, we transfected HCT116 and Wnt
autocrine U-2 OS cells with the CDC25A reporter and compared
relative activities of both wild and mutant reporter constructs. In
both tumor lines the wild-type CDC25A reporter exhibited
activity that was inhibited in the presence of dnTCF4 (Figure 6E).
When U-2 OS and HCT116 cells were cotransfected with the
mutant (DTCFB)-CDC25A reporter in the presence or absence606 Cancer Cell 19, 601–612, May 17, 2011 ª2011 Elsevier Inc.of dnTCF4, reporter activity was further decreased in HCT116
but not in U-2 OS cells, presumably due to reduced c-MYC tran-
scriptional function specific to the carcinoma cells (Figure 6E).
Thus, it is likely that CDC25A is both a direct and indirect TCF/
b-catenin target in Wnt-activated carcinoma cells.
Wnt Activity and In Vitro Differentiation Potential
of Human Sarcoma Cell Lines
High levels ofWnt signaling inhibit differentiation of hMSCs along
osteogenic or adipogenic lineages in vitro and in vivo (Liu et al.,
2009). Osteosarcoma cell lines, G-292, Saos2, SJSA-1, and
TE-85, exhibited the ability to differentiate along the osteogenic
lineage, as detected by staining for two markers of osteogenic
differentiation, alkaline phosphatase (AP) and alizarin red S (AR)
(Figure 7A). Wnt signaling is downregulated in MSCs during later
stages of osteogenic differentiation, allowing complete matura-
tion of osteoblasts to osteocytes (Li et al., 2005). We observed
a similar suppression ofWnt activity in G-292 and TE-85 cell lines
in which Wnt signaling was downregulated by more than 80%
under osteogenic induction conditions (Figures 7B and 7C). In
U-2 OS, which failed to differentiate in vitro, Wnt signaling was
downregulated less efficiently under osteogenic conditions
when compared to either G-292 or TE-85 cells (Figures 7B and
7C). Expression of AXIN2, which has been previously shown to
be downregulated during hMSC osteogenic and adipogenic
differentiation (Liu et al., 2009), decreased during osteogenic
differentiation in G-292 and TE-85 cells but was unaffected in
Figure 6. Lack of Correlation between Wnt Signaling and c-MYC Levels in Human Sarcomas
(A) Human sarcoma lines and HCT116 cells were stably transduced with dnTCF4, and proteins were analyzed by western blotting.
(B) Real-time PCR analysis of c-MYC andCyclinD1 in hMSCs treated with Wnt3A as described in Figure 3A. The values were normalized to TBP and represented
relative to those in untreated cultures (Control), which were set at one. Error bars indicate SD of mean values from triplicates and are representative of two
independent experiments.
(C) Western blot analysis of human sarcoma cell lines for c-MYC protein.
(D) c-MYC protein expression in protein extracts from frozen sections of primary sarcoma tissues. N, normal tissue; CS, chondrosarcoma; AS, angiosarcoma. All
other abbreviations for sarcomas are described in Figure 1. HT1080 and 143B lines were used as positive and negative controls for Wnt-activated sarcomas.
(E) HCT116 or U-2 OS cells were cotransfected with vector control, CDC25A-WT, or CDC25A-MT (see Figure 3F) luciferase reporter constructs (200 ng) and
a dnTCF4 expression construct (400 mg). Luciferase values were measured 48 hr posttransfection and normalized to Renilla. Error bars indicate SD of mean
values from triplicates and are representative of two independent experiments. **p < 0.01, ***p < 0.001 by Student’s t test.
See also Figure S5.
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under differentiation-inducing conditions, high Wnt activity in
osteosarcoma cells with osteogenic differentiation ability is
downregulated by an intrinsic mechanism.
None of the Wnt-activated sarcoma lines analyzed showed
evidence of multilineage differentiation capacity when exposed
to osteogenic (Figure 7E) or adipogenic (Figure S6A) differentia-
tion conditions in the absence or presence of Wnt downregula-
tion. These results suggested that Wnt-independent aberrations
might be responsible for the differentiation block. Frequent
genetic aberrations observed in sarcomas include highly specific
chromosomal translocations, as in the case of Ewing’s sarcoma,
synovial sarcoma, and alveolar rhabdomyosarcoma, and loss of
function mutations of Rb and p53 observed in osteosarcomas
(reviewed in Helman and Meltzer, 2003; Skubitz and D’Adamo,
2007). Thus, we sought to model genetic aberrations observed
in osteosarcomas by ectopic expression of cyclin-dependent
kinase 4 (CDK4) or dominant-negative p53 (dnp53), and
oncogenic rasG12D either alone or in combination in hMSCs.
The expression of any one of the three genes in addition to
hTERT, which did not itself block hMSC osteogenic differentia-
tion, was sufficient to partially inhibit AP expression without
exhibiting an obvious effect on mineralization as detected by
AR staining (Figure S6B). However, the severity of osteogenic
differentiation inhibition based on both reduced AP expression
and mineralization increased with the number of oncogenes
added. These findings argue that genetic alterations indepen-
dent of Wnt activation may mask the ability to correlate Wnt
activity with stemness in sarcomas.DISCUSSION
MSCs can differentiate along osteogenic, adipogenic, chondro-
genic, myogenic, and other connective tissue lineages in
response to specific differentiation media (Pittenger et al.,
1999). hMSCs have been shown to exhibit a low level of endoge-
nous Wnt signaling, which decreases in response to differentia-
tion stimuli (Li et al., 2005). Moreover, evidence that exogenous
Wnt stimulation specifically increased hMSC proliferation and in-
hibited differentiation (Liu et al., 2009), properties commonly
associated with tumor cells (Hanahan and Weinberg, 2000;
Liu et al., 2009; van de Wetering et al., 2002), led us to explore
whether Wnt upregulation might contribute to sarcomagenesis.
Our present studies establish constitutive Wnt activation relative
to levels observed in hMSCs in a diverse array of human
sarcomas. In contrast to colon carcinomas, in which Wnt activa-
tion involves genetic aberrations in intracellular components, we
established that Wnt activation in sarcomas commonly involves
an autocrine mechanism as shown by the ability of antagonists,
which act at the cell surface to blockWnt ligand/receptor interac-
tions, to downregulate this signaling. b-catenin mutations were
absent in any of the Wnt-activated sarcoma cell lines screened.
However, we identifiedAPC truncationmutations in two sarcoma
lines that lacked an autocrine-activation mechanism. Of note,
A2984 and SK-UT-1, like representative Wnt autocrine sarcoma
lines, were growth inhibited in response to dnTCF4, which had
no effects on Wnt negative sarcoma cells. These results
establish the Wnt specificity of this inhibition and the essential
role of Wnt signaling in driving the proliferation of sarcoma cellsCancer Cell 19, 601–612, May 17, 2011 ª2011 Elsevier Inc. 607
Figure 7. In Vitro Differentiation Properties
of Wnt-Activated Human Sarcoma Cells
(A) Sarcoma lines were plated at 10,000 cells/well
in 12-well plates and exposed to osteogenic
differentiation media (Diff.) for 2 weeks, followed
by fixation and staining for either AP (blue) or AR
(red). Control cells were maintained in basal
medium (Undiff.).
(B) Sarcoma lines stably expressing TOP- or FOP-
GFP reporters were cultured as described in (A),
and images were captured with a fluorescence
microscope or by phase contrast.
(C) TOP-luciferase reporter activity in sarcoma
cells cultured in basal or osteogenic differentiation
media. Values are normalized to Renilla. Normal-
ized values obtained for cells cultured in basal
media (Undiff.) were set at one.
(D) Real-time PCR measurement of AXIN2 using
total RNA extracted from sarcoma cells or hMSCs
cultured in the presence or absence of osteogenic
medium for 2 weeks as described in Figure 2C.
Normalized values obtained for cells cultured in
basal media (Undiff.) were set at one. Error bars
indicate SD ofmean values from triplicates and are
representative of two independent experiments.
(E) Sarcoma lines resistant to osteogenic differ-
entiation were cultured in the presence or absence
of osteogenic medium along with DKK1 (100 ng/
ml) added every other day for 2 weeks and stained
for AP and AR. Scale bars indicate 100 mm.
See also Figure S6.
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Upregulation of Wnt Activity in Human Sarcomasin which the pathway is upregulated. Furthermore,Wnt autocrine
activation contributes as significantly to the Wnt proliferative
drive as an APCmutation, previously established as the initiating
step in colon tumorigenesis (Bienz and Clevers, 2000; Korinek
et al., 1997; Morin et al., 1997; Polakis, 1997; Roose et al., 1999).
The frequency ofWnt activation was greater than 90% in oste-
osarcomas and was at least 50% in synovial, Ewing’s, rhabdo-
myo-, fibro-, and leiomyosarcoma cell lines. Constitutive Wnt608 Cancer Cell 19, 601–612, May 17, 2011 ª2011 Elsevier Inc.activation was also identified in primary
human sarcomas, which exhibited
elevated uncomplexed b-catenin levels
in more than 50% of samples analyzed
from a wide array of sarcoma subtypes.
There are reports implicating the hMSC
as the cell of origin for Ewing’s (Miyagawa
et al., 2008; Tirode et al., 2007) and MFH/
pleomorphic sarcomas (Matushansky
et al., 2007), and we detectedWnt activa-
tion in 50% of Ewing’s sarcoma cell lines.
Of note, hMSC adipogenic differentiation
is particularly sensitive to Wnt inhibition
(Ross et al., 2000), and the lowest
frequency of Wnt activation was ob-
served in sarcomas classified histopa-
thologically as liposarcomas. All of these
findings are consistent with a model in
which sarcomas commonly initiate from
upregulation of autocrine Wnt signaling,
and less frequently from mutations inintracellular components, in a MSC associated with its clonal
expansion and accumulation of additional alterations that
contribute to malignant transformation. However, our findings
do not exclude the possibility that Wnt pathway activation
occurs at some later stage of neoplastic progression and/or
involves a committed progenitor rather than a stem cell.
We observed that the sarcoma lines analyzed lackedmultiline-
age differentiation capacity, even under the conditions in which
Cancer Cell
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proliferation. Thus, if the target for Wnt pathway activation
were a mesenchymal stem/progenitor cell, Wnt-independent
alterations must override the differentiation potential of such
cells. In fact we found that oncogenic alterations of Rb, p53, or
Ras pathways, observed in osteosarcomas (Kansara and
Thomas, 2007), alone or in combination resulted in progressive
inhibition of the ability of hMSCs to undergo osteogenic differen-
tiation. These findings argue strongly that oncogenic alterations
independent of Wnt pathway activation can impair the ability of
a MSC to undergo lineage differentiation.
Mechanisms Involved in Activation of an Autocrine
Wnt Loop in Human Sarcomas
There are reports in the literature of nuclear accumulation of
b-catenin in a significant fraction (28%–57%) of synovial and
uterine soft tissue sarcomas without exploration of possible
mechanisms (Jung et al., 2008; Kildal et al., 2009; Ng et al.,
2005). Our present findings of Wnt autocrine activation establish
themolecular basis for nuclear accumulation of b-catenin in such
tumors. In a mouse model generated by loss of function of WIF1,
a Wnt antagonist, there was an increased incidence of radiation-
induced sarcomas (Kansara et al., 2009), and these same
authors identified epigenetic silencing of WIF1 in some human
osteosarcomas associated with upregulation of Wnt signaling
(Kansara et al., 2009). In contrast, Cai et al. (2010) recently re-
ported the inability to detect canonical Wnt activity in osteosar-
comas analyzed. Our present findings demonstrate activation
of this pathway by several different approaches in osteosarcoma
lines studied by Cai et al. (2010). Thus, the failure of Cai et al.
(2010) to detect Wnt pathway activation in human osteosar-
comas may involve differences in assay sensitivity.
Our findings that sarcomas of diverse types exhibit autocrine
canonical Wnt activation adds this tumor to those including
breast, ovarian, and lung carcinoma exhibiting autocrine Wnt
activation at high frequencies (Akiri et al., 2009; Bafico et al.,
2004). We observed that relative to hMSCs, sarcomas often
exhibited upregulated expression at the RNA level of canonical
Wnt ligands, most commonlyWnt7b andWnt10b. Sarcoma lines
also frequently overexpressed LRP5, LRP6, or both receptors,
with evidence of LRP5 gene amplification in some. Epigenetic
silencing of Wnt antagonists, including FRP1, FRP2, FRP4,
FRP5, DKK1, and DKK2, was identified in some sarcoma lines
as well. Thus, there appear to be several mechanisms by which
autocrine Wnt signaling can be upregulated in human sarcomas,
as demonstrated by the specific growth inhibition associated
with LRP5 and LRP6 downregulation in HOS and A204 sarcoma
lines, respectively. Our findings of more than one alteration in
Wnt cell surface components in some autocrine tumor lines
could imply continued selection for Wnt pathway activation by
this mechanism.
Cell Context Differences in the Role of Wnt Target
Genes in Tumor Cell Proliferation
Wnt signaling exerts its oncogenic functions via upregulation of
genes involved in cell cycle, exemplified by the positive TCF/
b-catenin transcriptional effects on c-MYC expression in carci-
nomas (Akiri et al., 2009; Bafico et al., 2004; van de Wetering
et al., 2002). c-MYC is required for efficient activation of allcyclin/CDK complexes and, thus, is a vital player acting at
multiple phases of the cell cycle (Mateyak et al., 1999). We
observed that unlike HCT116 colon carcinoma cells in which
c-MYC is responsible for Wnt-induced proliferation (He et al.,
1998; van de Wetering et al., 2002), c-MYC was not transcrip-
tionally regulated in a Wnt-dependent manner in Wnt-activated
sarcomas. Instead, we identified CDC25A as a Wnt transcrip-
tional target, as demonstrated by ChIP assay and b-catenin
dependent activation of CDC25A reporter in sarcoma cells.
Furthermore, we showed that CDC25A was an important medi-
ator of Wnt-induced sarcoma cell proliferation both in vitro and
in vivo. Although Wnt pathway downregulation in each sarcoma
line analyzed led to reduced CDC25A transcript and protein
levels, the level of CDC25A protein expression did not correlate
perfectly with Wnt activation among the sarcoma lines analyzed,
likely due to differences among tumor lines in CDC25A post-
translational regulation (Boutros et al., 2007). Recently, it was
reported that GSK3b, an effector kinase inhibited by Wnt
ligand-induced stimulation, regulates CDC25A protein levels
by proteasome-mediated degradation (Kang et al., 2008).
Thus, GSK3b inhibition by autocrine Wnt activation could in
theory lead to increased CDC25A protein stabilization. However,
our results provide no evidence for Wnt-dependent regulation of
CDC25A expression at the protein level by such a mechanism.
CDC25A is overexpressed in multiple cancers, including
breast, ovarian, lung, colorectal, pancreatic, and head and
neck cancer (reviewed in Boutros et al., 2007). It is inferred
from animal studies that among the CDC25 family, CDC25A
plays a nonredundant role in regulating cell cycle (Chen et al.,
2001; Ferguson et al., 2005; Ray et al., 2007b). MMTV-targeted
expression of CDC25A cooperated with neu or ras-induced
mammary tumorigenesis, whereas mice hemizygous for
Cdc25A exhibited prolonged latency of neu or ras-induced
mammary tumors (Ray et al., 2007a; Ray et al., 2007b).
CDC25A is also transcriptionally regulated by c-MYC as well
as by E2F1 in mammalian cells (Galaktionov et al., 1996; Vigo
et al., 1999). Given that CDC25A is a transcriptional target of
both TCF/b-catenin, as shown here, and c-MYC (Galaktionov
et al., 1996), the inhibition of proliferation induced by dnTCF4
in colon and other carcinomas may be mediated through
CDC25A as well as c-MYC.
In summary our present studies show that the Wnt canonical
upregulation by autocrine or, less frequently, by other mecha-
nisms is common in human sarcomasofmany subtypes. Further-
more, Wnt upregulation by autocrine activation or other mecha-
nisms plays an important causal role in the proliferative drive of
Wnt-activated sarcomas through a Wnt target gene, CDC25A.
Over the past two and a half decades since the discovery of the
involvement of activated tyrosine kinase receptor pathways in
tumors, agents that specifically target these pathways have
provided clinically useful adjuvants to standard chemo-irradia-
tion therapies (reviewed in Zhang et al., 2009). The high preva-
lence of Wnt pathway activation in human sarcomas described
here and the ability to identify Wnt pathway activation in primary
sarcoma tissues make it reasonable to test whether naturally
occurring Wnt antagonists such as DKK1 or FRP or recently
reported small molecule Wnt inhibitors (Doghman et al., 2008;
Huanget al., 2009)maycomplement standard agents in the treat-
ment of this most common childhood malignancy.Cancer Cell 19, 601–612, May 17, 2011 ª2011 Elsevier Inc. 609
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Uncomplexed b-Catenin Analyses
Immunoprecipitation to detect uncomplexed b-catenin was performed as
described previously (Bafico et al., 2004). Briefly, 1 mg of protein from
whole-cell lysate was incubated with GST-E-cadherin/Glutathione-Sepharose
beads (Amersham) for 1 hr at 4C. Beads were pelleted and washed thrice in
lysis buffer and resuspended in loading buffer for western blot analysis as
described in Supplemental Experimental Procedures.
Human Sarcoma Tissues
Frozen sarcoma tissues were purchased from NCI’s Cooperative Human
Tissue Network or obtained through the Tisch Cancer Institute’s Biorepository
at Mount Sinai Hospital. Sarcoma tissues acquired from the Mount Sinai
Hospital used in this study were de-identified prior to analysis. The use of
human tissues was approved by the Institutional Review Board. Frozen tissues
were embedded in Optimal Cutting Temperature (OCT), and 20 sections of
20 mm each were used. Tumor tissues were analyzed histologically to confirm
the presence of at least 70% tumor cells. Excess OCT was removed, and
tissues were rinsed thrice in cold PBS. Buffer containing 1% NP-40,
150 mM sodium chloride, and protease inhibitors was used for protein
solubilization.
Microarray
Total RNA extracted from hMSCs was used for gene expression analysis on
the GeneChip Human Genome U133A 2.0 Array (Affymetrix). Hybridization
and data acquisition were conducted at Mount Sinai’s Microarray Shared
Research Facility according to the manufacturer’s protocol. Data were
analyzed using GeneChip Operating Software (Affymetrix) and Ingenuity’s
Pathway Analysis software.
In Vivo Tumorigenicity Assay
HT1080 cells stably expressing firefly luciferase were transduced with vector
control, dnTCF4, or CDC25A shRNA and selected as described for colony-
forming assay. Firefly luciferase was cloned in a lentiviral vector carrying
a neomycin marker gene. Standard procedures were used to clone the full-
length CDC25A cDNA into a PGK promoter-driven lentiviral construct contain-
ing a blasticidin marker gene. Cells expressing both dnTCF4 and CDC25A
were selected inmedium containing 1 mg/ml puromycin and 5 mg/ml blasticidin
(Invitrogen). Around 1 3 106 cells were resuspended in PBS and mixed with
50% Matrigel (BD Biosciences) prior to subcutaneous inoculation at two sites
in 6-week-old athymic nudemice (NCI). All animal experiments were approved
and performed according to the relevant regulatory standards set by Mount
Sinai’s Animal Care andUseCommittee. Mice were anesthetized using isoflur-
ane, and in vivo imaging was performed using the Xenogen IVIS-200 Imaging
System at Mount Sinai’s shared in vivo imaging facility.
Osteogenic and Adipogenic Differentiation Assay
Cells were transferred to 24-well plates and cultured in either basal medium
(DMEM, 10% FBS, 100 U/m P/S) or osteogenic medium consisting of
DMEM, 10% FBS, 100 U/m P/S supplemented with 50 mg/ml ascorbic acid
(Biochemika), 10 mM b-glycerol-2-phosphate (Sigma), and 1 mM dexametha-
sone (Sigma). Cells were subjected to differentiation conditions for around
2 weeks and processed for staining as described previously (Liu et al.,
2009). Adipogenic differentiation was performed as previously described
(Liu et al., 2009).
Statistical Analyses
Statistical significance was determined with Student’s t test or one-way anal-
ysis of variance (ANOVA) in the case of more than two comparisons (calculated
with GraphPad Prism 5 software).
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